AnaptysBio, Inc (ANAB) stock

ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 9/30

$49.24+2.63 (+5.64%)

Close on Oct 19, 2026Market cap $1.73BP/E –Yield –

AnaptysBio EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

AnaptysBio's EV/EBITDA was 4.2× on Oct 19, 2026, against 4.9× a year earlier. Over the last 2 years it ranged from 0.9× to 31.6×, with a median of 4.2×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2026	Oct 19, 2026	4.2×	−0.1
2025	Dec 31, 2025	4.2×	−21.3
2022	Jan 31, 2022	25.5×	−6.1
2021	Dec 31, 2021	31.6×	–

Where these numbers come from

Parsed from the XBRL in AnaptysBio's annual and quarterly filings with the SEC
Per-share figures adjusted for the 15-for-10 split on Apr 20, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ANAB.

Compare: ANAB vs ZYME · ANAB vs XNCR · ANAB vs IDYA · ANAB vs LGND · ANAB vs SNDX

Revenue growth13.0% · median 65.7%

Operating margin155.6% · median -61.7%

Net margin96.3% · median -58.8%

Company	Revenue	Growth
SNDX	$289.68M	+159.7%
ZYME	$265.97M	+97.8%
LGND	$253.83M	+1.0%
IDYA	$234.13M	–
XNCR	$200.49M	+33.5%
ANAB	$191.57M	+13.0%

Company

Next earnings (est.): Mar 2, 2027, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: June 30
Employees: 104
Held by institutions: 100.0%
Auditor: KPMG LLP
SEC CIK: 1370053

Advertisement
300 × 250

See a number that looks wrong?

AnaptysBio EV/EBITDA

EV/EBITDA at the end of each year

More AnaptysBio figures